Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
SPRIX, 13% Increase in Ordinary Profit for The Current Fiscal Year
7030 SPRIX Inc. 【J-GAAP】
Earnings ReportSPRIX Inc. <7030> [TSE Std] announced its financial results after the market closed on November 13th (15:30). The consolidated ordinary profit for the fiscal year ended September 2025 expanded to 95.6% from the previous period to 2.21 billion yen. For the fiscal year ending September 2026, the consolidated ordinary profit is expected to grow by 12.7% to 2.50 billion yen. This will be the thirteenth consecutive term of revenue growth.
In the most recent three-month period, from July to September (4Q), the consolidated ordinary profit increased 52.3% from the same period last year, reaching 1.43 billion yen. The operating profit margin jumped from 10.4% in the same period last year to 13.8%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Sep, 2023 | 30,363 | 1,318 | 1,319 | 561 | 32.5 | 38 | Nov 10, 2023 | J-GAAP |
| Sep, 2024 | 31,860 | 1,093 | 1,134 | 500 | 28.7 | 38 | Nov 12, 2024 | J-GAAP |
| Sep, 2025 | 35,127 | 2,170 | 2,218 | 1,087 | 61.7 | 38 | Nov 13, 2025 | J-GAAP |
| YoY | +10.3% | +98.5% | +95.6% | +117.4% | +115.2% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Sep, 2025 Guidance | 35,127 | 2,170 | 2,218 | 1,087 | 61.7 | 38 | Nov 11, 2025 | J-GAAP |
| Sep, 2025 Results | 35,127 | 2,170 | 2,218 | 1,087 | 61.7 | 38 | Nov 13, 2025 | J-GAAP |
| Revision Rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Mar, 2024 | 17,223 | 1,135 | 1,149 | 703 | 40.0 | 19 | May 13, 2025 | J-GAAP |
| Oct - Mar, 2025 Guidance | ー | ー | ー | ー | - | 19 | Nov 13, 2025 | J-GAAP |
| YoY | - | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Sep, 2024 | 31,860 | 1,093 | 1,134 | 500 | 28.7 | 38 | Nov 12, 2024 | J-GAAP |
| Sep, 2025 | 35,127 | 2,170 | 2,218 | 1,087 | 61.7 | 38 | Nov 13, 2025 | J-GAAP |
| Sep, 2026 Guidance | 38,000 | 2,400 | 2,500 | 1,400 | 79.4 | 38 | Nov 13, 2025 | J-GAAP |
| YoY | +8.2% | +10.6% | +12.7% | +28.8% | +28.5% |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jul - Sep, 2024 | 9,079 | 940 | 943 | 473 | 27.1 | 10.4 | Nov 12, 2024 | J-GAAP |
| Oct - Dec, 2024 | 8,707 | 1,171 | 1,189 | 730 | 41.6 | 13.4 | Feb 13, 2025 | J-GAAP |
| Jan - Mar, 2025 | 8,516 | -36 | -40 | -27 | -1.5 | -0.4 | May 13, 2025 | J-GAAP |
| Apr - Jun, 2025 | 7,692 | -374 | -367 | -286 | -16.3 | -4.9 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 10,212 | 1,409 | 1,436 | 670 | 38.1 | 13.8 | Nov 13, 2025 | J-GAAP |
| YoY | +12.5% | +49.9% | +52.3% | +41.6% | +40.2% |
Related Articles
Sanyo Electric Railway, Ordinary Profit Forecast for the Fiscal Year Revised Upward to an Unexpected 2% Increase, Dividend Revised Upward by 10 Yen
logly, First Half Ordinary Profit Loss Narrows, Jul-Sep Ordinary Profit Loss Narrows
CAPITA, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 6%, Dividend Revised Upward by 6 Yen
Japan Animal Referral Medical, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 20%, Raises Record High Profit Forecast
Noile-Immune Biotech, The Current Fiscal Year's Undisclosed Net Income to Narrow
ITFOR, First Half Ordinary Profit Revised Downward to an Unexpected 21%Decrease, Current Fiscal Year Dividend Revised Upward by 20 Yen
Jibannet, First Half Net Income Turns to Loss, Jul-Sep Net Income Decreases by 40%
FRUTA FRUTA, First Half Ordinary Profit Increases by 3.7 times, Jul-Sep Ordinary Profit Increases by 40%
jig.jp, First Half Ordinary Profit Decreases by 3%, Jul-Sep Ordinary Profit Decreases by 11%
JAPAN INSULATION, First Half Ordinary Profit Increases by 73%, Jul-Sep Ordinary Profit Increases by 65%